Anlotinib Recruiting Phase 2 Trials for Hepatocellular Carcinoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04080154Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma
NCT04157140Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
NCT02809534A Study of Anlotinib in Patients With Hepatocellular Carcinoma
NCT04066543TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients